Quality of Evidence for Prenatal Down Syndrome Screening: An Umbrella Review
Prenatal Diagnosis · 2026-08 · 46 (9) · 1434-1446
DOI: 10.1002/pd.70191 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Prenatal Diagnosis, online erschienen am 02.06.2026. Verfasst von Yuehua Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Health Statistics, College of Public Health, Zhengzhou University, Zhengzhou, Henan Province, China. Hauptthemen laut MEDLINE: Down Syndrome, Prenatal Diagnosis, Noninvasive Prenatal Testing. Die Arbeit nennt 83 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Henan Science and Technology Department.
Abstract (Originalsprache)
Objective
Many systematic reviews (SRs) report the accuracy of prenatal Down syndrome screening, but their methodological quality has not been comprehensively evaluated. This umbrella review assessed the quality, compared non‐invasive prenatal testing (NIPT) with traditional screening, and evaluated the findings' robustness.
Method
We searched MEDLINE, Embase, and multiple other databases from inception to March 24, 2026, for SRs, including gray literature sources as specified in the methods. Methodological quality, risk of bias, and evidence certainty were assessed using AMSTAR 2, ROBIS, and GRADE. The study was registered with PROSPERO (CRD42024597291).
Results
Of 42 included SRs, NIPT and combined screening were the most common. AMSTAR 2 ratings indicated that 88.1% (37/42) of SRs were of low or critically low confidence; 66.7% SRs were judged to have a high risk of bias; and high‐quality evidence was scarce (9.6%). Despite this, NIPT's higher accuracy was maintained in sensitivity analyses, showing higher sensitivity (93.0%–100.0%) and specificity (96.0%–100.0%) than traditional methods, which showed wider performance variation (e.g., biochemical screening sensitivity: 28.0%–89.0%).
Conclusion
The methodological quality of SRs evaluating Down syndrome screening is limited. Nevertheless, NIPT consistently shows higher accuracy than traditional screening. NIPT implementation should be prioritized where feasible, while future primary research requires large, prospective studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Epidemiology and Health Statistics, College of Public Health, Zhengzhou University, Zhengzhou, Henan Province, China.
- Department of Prenatal Diagnosis Center, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.
- Department of Clinical Epidemiology, Henan Children's Hospital, Zhengzhou Children's Hospital, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou, Henan Province, China.
- Key Laboratory of Tumor Epidemiology of Henan Province, State Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, Zhengzhou University, Zhengzhou, Henan Province, China.
ORCID-Profile: Ling Liu, Kaijuan Wang
Förderung
- Henan Science and Technology Department
Zitieren
APA
Zhang, Y., Wang, Y., Wang, X., Liu, L., & Wang, K. (2026). Quality of Evidence for Prenatal Down Syndrome Screening: An Umbrella Review. Prenatal Diagnosis, 46(9), 1434-1446. https://doi.org/10.1002/pd.70191
Vancouver
Zhang Y, Wang Y, Wang X, Liu L, Wang K. Quality of Evidence for Prenatal Down Syndrome Screening: An Umbrella Review. Prenatal Diagnosis. 2026;46(9):1434-1446. doi:10.1002/pd.70191
BibTeX
@article{Zhang2026,
author = {Zhang, Yuehua and Wang, Yingying and Wang, Xinlong and Liu, Ling and Wang, Kaijuan},
title = {Quality of Evidence for Prenatal Down Syndrome Screening: An Umbrella Review},
journal = {Prenatal Diagnosis},
year = {2026},
volume = {46},
number = {9},
pages = {1434--1446},
doi = {10.1002/pd.70191}
}
EUVIMED